T H E N I H C A T A L Y S T | M A Y J U N E 2008 |
|
C O M M E N T A R YTHE DUAL CHALLENGES PRESENTED BY DUAL-USE RESEARCH
|
|
![]() |
Henry Metzger
|
This essay is intended to open a dialogue for a plan of action for evaluating dual-use research both before it is undertaken and before publication.
An investigator decides to develop
a
vaccine against a select toxin
known
for its resistance to conventional denaturing conditions. After purifying the
toxin in the usual way, he adds a rather simple step and finds that on testing
in mice, the oral LD50 is 0.1
percent that reported in the literature! (Lethal Dose 50 is the dose at which 50% of the animals die.)
This result, taken from a real
occurrence, is a typical example of “dual-use research”—that is, research
that may generate valuable scientific knowledge but that could also be
deliberately used to create serious harm to the public health or the
environment.
Whether the investigator should
publish this finding is the dual challenge presented by dual-use research
results. On the one hand, it is important to publicize the findings so that
others can make use of the new knowledge to our mutual benefit; on the other
hand, one wishes to avoid dissemination of information that could easily be
used by someone to create havoc.
That advances in biotechnology
require only relatively simple resources to be misused for destructive purposes
has long been recognized, but the terrorist activities of September 11, 2001,
and the deliberate dissemination of anthrax spores shortly thereafter magnified
this concern within both the scientific community and the public at large.
A keyword search for “bioterrorism” within the PubMed
database fails to yield a single hit before 1996, but in 2002, the peak year,
almost 900 citations are listed. In parallel, potential dual-use research results
such as those listed in Table 1 have appeared on the front pages and in op-eds
of the nation’s most influential newspapers, and they have raised controversies
about their publication in the halls of Congress.
Academies of science in the United
States, the United Kingdom, and elsewhere have organized conferences on the
subject; an in-depth monograph on the subject by the U.S. National Research
Council (Biotechnology Research in an Age of Terrorism, 2004) has been particularly
influential. Professional societies—in particular, the American Society
for Microbiology and FASEB—have promoted discussions of the issues, and
the U.S. government responded by creating a National Science Advisory Board on
Biosecurity in 2004.
The Board’s membership includes
representatives of government security agencies, health
agencies—including, of course, the NIH—and academia and industry.
Its “Proposed
Framework for Oversight of Dual Use Life Science Research: Strategies for
Minimizing the Potential Misuse of Research Information” was issued for public comment in
June 2007. Special emphasis has been directed towards those areas of research
that are of most obvious concern such as those listed in Table 2.
The importance of international
co-operation for dealing with the challenge of dual-use research is self-evident.
A second “Forum on Biosecurity (see agenda and PowerPoint presentations),” attended by 31 countries and sponsored by
eight international organizations, was held March 31–April 2, 2008, in
Budapest.
All those considering this subject
have emphasized the foremost importance of educating members of the research
community about the dual-use research dilemma, recognizing that, as with recombinant
DNA research, the scientific community itself is in the best position to
properly balance the advantages of open unfettered research and communication
of its results and the need to protect the public from harm.
Table 3 lists the annual number of
deaths from various causes over the five-year period from 2002 to 2006. It
would be a tragedy if by self- or government-imposed censorship occasioned by
the threat of misuse, research directed towards the biological, behavioral, and
social factors responsible for the major causes of death and morbidity were to
be constrained.
The best
way to avoid that scenario is for the scientific community to provide credible
evidence that it is willing and able to deal responsibly with the public’s
legitimate concerns.
Table 1. Recent Examples
Of Published
“Contentious Research”
|
|
Table 2. Principal Types
Of Research Results
That Raise Dual-Use Concerns
|
Findings that:
|
Table 3. World Mortality
Statistics
|
|
Cause
|
Incidence
Per Year
(2002–2006)
|
Communicable diseases and maternal, perinatal, and
nutritional conditions
Noncommunicable
diseases
Injuries (intentional
and nonintentional)
Bioterrorism
|
18,400,000
33,500,000
5,200,000
1
|